

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7979910

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
George Costas Avgerinos	02/23/2023
Patrick Michael Hossler	02/24/2023
Jill A. Myers	02/24/2023
Yune Z. Kunes	02/24/2023
RECEIVING PARTY DATA	
Name:	TG THERAPEUTICS, INC.
Street Address:	2 GANSEVOORT STREET
Internal Address:	9TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10014
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18167631
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (617) 521-7023
Email:	apsi@fr.com
Correspondent Name:	PALLAVI BANERJEE
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	50581-0004004
NAME OF SUBMITTER:	MARY FLORCZAK
SIGNATURE:	/Mary Florczak/
DATE SIGNED:	05/30/2023
Total Attachments: 5	

source=assignment-signed (1)#page1.tif
source=assignment-signed (1)#page2.tif
source=assignment-signed (1)#page3.tif
source=assignment-signed (1)#page4.tif
source=assignment-signed (1)#page5.tif

ASSIGNMENT

For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, GEORGE COSTAS AVGERINOS, PATRICK MICHAEL HOSSLER, JILL A. MYERS, and YUNE Z. KUNES, each individually assign to TG THERAPEUTICS, INC., a corporation having a principal place of business at 2 Gansevoort Street, 9th Floor, New York, NY 10014, and its successors, transferees, and assignees (collectively the “Assignee”), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the “Subject Matter”) described in a patent application that names us as inventors, is titled “ANTI-CD20 ANTIBODY COMPOSITIONS,” and was filed in the United States Patent and Trademark Office on February 10, 2023, as application 18/167,631 (the “Application”).

This Assignment assigns, in addition to the Subject Matter, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors’ certificates for, any of the Subject Matter (collectively the “Applications and Granted Rights”) in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, the Hague Agreement, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee’s name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee’s name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

DocuSigned by George Avgerinos



George Avgerinos

I have reviewed this document
23-Feb-2023 | 11:00:48 AM EST

23-Feb-2023

Date:

GEORGE COSTAS AVGERINOS
1536A3075E1546A0F0E338C6C0457D21

Witnessed by:

Signature: _____

Date: _____

Print Name: _____

Signature: _____

Date: _____

Print Name: _____

DocuSigned by Patrick Hossler



Patrick Hossler

I approve this document
24-Feb-2023 | 6:05:43 PM EST

24-Feb-2023

Date: _____

PATRICK MICHAEL HOSSLER

30626C22C970642678F1B9C858630C8D94

Witnessed by:

Signature: _____

Date: _____

Print Name: _____

Signature: _____

Date: _____

Print Name: _____

DocuSigned by: Jill Myers



Jill Myers

I approve this document
24-Feb-2023 | 5:05:48 PM EST

24-Feb-2023

Date: _____

JILL A. MYERS

FC088EA09C3F43B49412E7A1C88AF276

Witnessed by:

Signature: _____


Date: _____

Print Name: _____

Signature: _____

Date: _____

Print Name: _____

DocuSigned by Yune Kunes
 Yune Kunes | I approve this document
24-Feb-2023 | 8:53:31 PM EST

Date: 24-Feb-2023

YUNE Z. KUNBS-5D28B908A8994C320BA6D7601971165B8

Witnessed by:

Signature: _____

Date: _____

Print Name: _____


Signature: _____

Date: _____

Print Name: _____

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: TG THERAPEUTICS, INC.

Signature: _____ DocuSigned by Hari Miskin
 Hari Miskin | I approve this document
02-Mar-2023 | 11:41:39 AM EST Date: 02-Mar-2023

Name: Hari Miskin
F035EAB8082549816091139FE1D83A95

Title: Chief Development Officer

24283542.doc